BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes

BACKGROUND: Combined inhibition of BRAF/MEK is an established therapy for melanoma. In addition to its canonical mode of action, effects of BRAF/MEK inhibitors on antitumor immune responses are emerging. Thus, we investigated the effect of these on adaptive immune responses. PATIENTS, METHODS AND RE...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Immunother
Autors principals: Peiffer, Lukas, Farahpour, Farnoush, Sriram, Ashwin, Spassova, Ivelina, Hoffmann, Daniel, Kubat, Linda, Stoitzner, Patrizia, Gambichler, Thilo, Sucker, Antje, Ugurel, Selma, Schadendorf, Dirk, Becker, Jürgen C.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2020
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8139931/
https://ncbi.nlm.nih.gov/pubmed/33275172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-020-02804-4
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars